ALERT: Due to the inclement weather across much of the country, Medtronic deliveries are currently experiencing delays and there will be longer than normal hold times on the phone. Visit www.Diabetes.shop if you need to place an order, get a sensor or belt clip replacement, or check the status of your supply order. X
Image of man and girl

Why Medtronic is
the right choice


At Medtronic, we aim to provide you the right solution at the right time, wherever you are in your diabetes journey. Our focus is to help you achieve better glucose control and spend less time managing highs and lows.


See our products

Transforming diabetes care together, for greater freedom and better health

A family of solutions


We develop technologies that allow you to focus more on life and less on diabetes. View our portfolio of products designed to meet you wherever you may be in your diabetes journey (click on each image to view more).

Product access icon

Product access and assistance programs

People icon

Inclusion and health equity solutions for all insulin-taking people with diabetes

Dedicated team icon

Dedicated team of experts available 24 hours a day

Support every step of the way

As your partner in care, we are here to help wherever you are on your diabetes journey.


Help choosing the right therapy

Help choosing the right therapy
Our therapy specialists can help you review your options as you choose the best therapy for you. They can help verify your insurance.

Assistance
programs

Assistance programs
Living with diabetes comes with many barriers. Getting access to technology shouldn't be one of them. Learn more

Hands-on product
training

Hands-on product training
In-person or online trainings help you get started on the right foot and make sure you have everything you need to be successful on your new therapy.

24-Hour Technical
Support

24-Hour Technical Support
We offer round-the-clock support for any issues you might encounter. When you need us call 1-800-646-4633 and select option 1.

Online educational
resources

Online educational resources
Interested in learning more about your diabetes device on your own? We offer a variety of resources available online to help.

Clinical
support

Clinical guidance
If you’re looking for ways to improve your diabetes management, you always have the option to request a meeting with a clinical trainer to discuss any factors that may be impacting your sugar levels. CareLink software converts data from your device into easy to understand reports that can be used during doctor's visits.

Real customer care experiences


Support every step of the way



Medtronic diabetes product portfolio - Guardian™ Connect system, InPen™, i-Port Advance™ injection port and MiniMed 770G™ system

Start your journey with Medtronic today

For information about our solutions that are currently available, complete the form or call today at 888-680-2280 (M-F 9AM-6PM CT).


Are you an existing Medtronic Customer?
 

*indicates fields that are required

Which product are you interested in learning more about? (please check the boxes below)

* Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary.
† Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.
†† Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.
∆ Not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
1. Riley D, Raup G. Impact of a subcutaneous injection device on improving patient care. Nurs Manage. 2010;41(6):49-54.
2. Injection port lets you take your medication without having to puncture your skin for each shot.

Important Safety Information: MiniMed 770G System With SmartGuard Technology
The MiniMed 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 770G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Medtronic MiniMed 770G System consists of the following devices: MiniMed 770G Insulin Pump, the Guardian Link (3) Transmitter, the Guardian Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.

The Guardian Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian Sensor (3).

All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.

WARNING: Do not use the SmartGuard Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard Auto Mode.

WARNING: Do not use the MiniMed 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed 770G system.

Important Safety Information: MiniMed 630G System with SmartGuard Technology
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.

WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard™ feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.

Important Safety Information: Guardian Connect CGM System
The Guardian Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.

The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices and not on values provided by the system.

Important Safety Information: i-Port Advance Injection Port
i-Port Advance™ injection port is indicated for patients who administer or receive multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple injections without the discomfort of additional needle sticks. i-Port Advance™ injection port may be used on a wide range of patients, including adults and children. Prescription required. For more, please see http://www.medtronicdiabetes.com/important-safety-information.

Important Safety Information: InPen
The InPen is a home- use reusable pen injector for single- patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self- injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient- specific criteria and targets. The InPen requires a prescription. For additional product and safety information, please consult the Instructions for Use and bit.ly/InPenRisks.

Roche logo

Roche and Roche logo are trademarks and/or registered trademarks of F. Hoffmann-La Roche Ltd.